Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LANCL-based Therapy
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : NImmune Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
NImmune Biopharma Collaborates with BioTherapeutics For Precision Immunology Drugs
Details : NImmune will leverage BioTherapeutics’ computational and preclinical services to accelerate biomarker-driven development of its LANCL immunoregulatory drug pipeline.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
September 05, 2024
Lead Product(s) : LANCL-based Therapy
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : NImmune Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?